EVOTEC BioSystems AG
26 October 2000

Not  for  release, publication or distribution in or into the  United  States,
Australia, Canada or Japan.


                        EVOTEC BioSystems AG ('EVOTEC')
                Compulsory acquisition of outstanding shares in
                  Oxford Asymmetry International plc ('OAI')

EVOTEC  announces  that valid acceptances in respect of the  Offer  have  been
received  in respect of more than 90 per cent. in value of the OAI  Shares  to
which  the Offer relates.  Accordingly, EVOTEC will as soon as practicable  be
posting  formal notices to OAI Shareholders who have not yet validly  accepted
the  Offer  informing such OAI Shareholders that it will compulsorily  acquire
their OAI Shares under the provisions of Sections 428 - 430F of the Act.

On 29 September 2000, EVOTEC announced that the Offer was unconditional in all
respects  and  would remain open until further notice.  EVOTEC  now  announces
that the Offer will be closed at 3.00 p.m. on 17 November 2000 and will not be
capable of acceptance thereafter.  Accordingly, after 3.00 p.m. on 17 November
2000,  all  outstanding  OAI  Shares will be  acquired  under  the  compulsory
acquisition procedure referred to above.

Notice  is  hereby  given that the Directors of OAI intend to  apply  for  the
removal  of the OAI Shares from the Official List of the UK Listing  Authority
('delisting')  and  for the cancellation of trading in  OAI's  Shares  on  the
London Stock Exchange's markets for listed securities and it is intended  that
such delisting and cancellation will take effect on 1 December 2000.


Enquiries

Lehman Brothers                                      Tel:  +44 (0)20 7601 0011
Warwick Ball
Joanna Floyd

Definitions  used  in the offer document dated 12 August 2000  have  the  same
meanings   when  used  in  this  announcement,  unless  the  context  requires
otherwise.

Lehman  Brothers, which is regulated in the UK by The Securities  and  Futures
Authority Limited, is acting for EVOTEC BioSystems AG in connection  with  the
Offer  and no-one else and will not be responsible to anyone other than EVOTEC
BioSystems  AG for providing the protections afforded to customers  of  Lehman
Brothers, nor for providing advice in relation to the Offer.

The  Offer  is  not being made, directly or indirectly, in or into  Australia,
Canada  or  Japan, and it may not be accepted in or from Australia, Canada  or
Japan.  In addition, the Offer is not being made, directly or indirectly in or
into the United States, and, subject to certain exceptions, the Offer may  not
be accepted from the United States.

The  New EVOTEC Shares proposed to be issued in connection with the Offer will
not  be  registered under the U.S. Securities Act of 1933, as  amended.   This
announcement does not constitute an offer of securities for sale in the United
States.  No public offering of securities will be made in the United States in
connection with the Offer.